颅内刺激治疗难治性疼痛障碍的疼痛缓解率及预测因素
该研究对36个研究组663例植入DBS或MCS的难治性疼痛患者进行个体患者数据回顾,发现MCS与DBS外部试验成功率相似(86% vs 81%;P=.16),外周痛较中枢痛试验成功率更高(88% vs 79%;P=.004)。全部植入患者末次随访平均疼痛缓解45.8%(95%CI:40.3-51.2),生活质量改善31.2%(95%CI:12.4-50.1)。
要点
- MCS与DBS外部试验成功率相似(86% vs 81%;P=.16),并发症率也相似(12% vs 15%;P=.79)。
- 外周痛较中枢痛试验成功率更高(88% vs 79%;P=.004),设备停止率更低(5.7% vs 10%;P=.03)。
- 全部植入患者末次随访平均疼痛缓解45.8%(95%CI:40.3-51.2),生活质量改善31.2%(95%CI:12.4-50.1)。
核心结论
- DBS与MCS治疗难治性疼痛的疗效和并发症率相似。
- 中枢性疼痛患者倾向于有较低的试验成功率和较高的设备停止率。
- 前扣带皮层靶点与较差的疼痛缓解相关,带状疱疹后神经痛是阳性预后因素。
研究设计与样本
- 对36个研究组663例植入DBS或MCS设备的患者进行个体患者疼痛结局回顾。
- 纳入研究主要为回顾性队列研究。
主要发现
- MCS患者外部试验成功率与DBS患者相似(86% vs 81%;P=.16)。
- 外周痛患者试验成功率高于中枢痛患者(88% vs 79%;P=.004)。
- MCS与DBS患者并发症率相似(12% vs 15%;P=.79)。
- 外周痛患者设备停止率低于中枢痛患者(5.7% vs 10%;P=.03)。
- 全部植入患者末次随访平均疼痛缓解45.8%(95%CI:40.3-51.2),生活质量改善31.2%(95%CI:12.4-50.1)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Intracranial modulation paradigms, namely deep brain stimulation (DBS) and motor cortex stimulation (MCS), have been used to treat intractable pain disorders. However, treatment efficacy remains heterogeneous, and factors associated with pain reduction are not completely understood. METHODS: We performed an individual patient review of pain outcomes (visual analog scale, quality-of-life measures, complications, pulse generator implant rate, cessation of stimulation) after implantation of DBS or MCS devices. We evaluated 663 patients from 36 study groups and stratified outcomes by pain etiology and implantation targets. RESULTS: Included studies comprised primarily retrospective cohort studies. MCS patients had a similar externalized trial success rate compared with DBS patients (86% vs 81%; P = .16), whereas patients with peripheral pain had a higher trial success rate compared with patients with central pain (88% vs 79%; P = .004). Complication rates were similar for MCS and DBS patients (12% vs 15%; P = .79). Patients with peripheral pain had lower likelihood of device cessation compared with those with central pain (5.7% vs 10%; P = .03). Of all implanted patients, mean pain reduction at last follow-up was 45.8% (95% CI: 40.3-51.2) with a 31.2% (95% CI: 12.4-50.1) improvement in quality of life. No difference was seen between MCS patients (43.8%; 95% CI: 36.7-58.2) and DBS patients (48.6%; 95% CI: 39.2-58) or central (41.5%; 95% CI: 34.8-48.2) and peripheral (46.7%; 95% CI: 38.9-54.5) etiologies. Multivariate analysis identified the anterior cingulate cortex target to be associated with worse pain reduction, while postherpetic neuralgia was a positive prognostic factor. CONCLUSION: Both DBS and MCS have similar efficacy and complication rates in the treatment of intractable pain. Patients with central pain disorders tended to have lower trial success and higher rates of device cessation. Additional prognostic factors include anterior cingulate cortex targeting and postherpetic neuralgia diagnosis. These findings underscore intracranial neurostimulation as an important modality for treatment of intractable pain disorders.
引用
- Huang Y, Sadeghzadeh S, Li AH, et al. Rates and Predictors of Pain Reduction With Intracranial Stimulation for Intractable Pain Disorders. Neurosurgery. 2024. PMID: 38836613. doi:10.1227/neu.0000000000003006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。